Tommy Thompson Sells 2,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Tommy Thompson sold 2,000 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $489.42, for a total transaction of $978,840.00. Following the completion of the transaction, the director owned 8,480 shares in the company, valued at approximately $4,150,281.60. This trade represents a 19.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Trading Down 1.1%

Shares of NASDAQ UTHR traded down $5.15 during midday trading on Thursday, reaching $485.06. 420,755 shares of the stock were exchanged, compared to its average volume of 381,036. The stock has a 50 day moving average price of $483.67 and a 200-day moving average price of $450.90. The company has a market capitalization of $21.26 billion, a P/E ratio of 17.39, a P/E/G ratio of 1.79 and a beta of 0.84. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $537.19.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the business earned $6.19 earnings per share. On average, analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Several institutional investors have recently bought and sold shares of UTHR. Geneos Wealth Management Inc. raised its stake in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Envestnet Asset Management Inc. boosted its position in United Therapeutics by 1.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 73,072 shares of the biotechnology company’s stock worth $20,995,000 after purchasing an additional 1,163 shares during the period. Hantz Financial Services Inc. raised its position in United Therapeutics by 1,950.0% in the second quarter. Hantz Financial Services Inc. now owns 246 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 234 shares during the period. Atria Investments Inc lifted its stake in shares of United Therapeutics by 12.6% during the second quarter. Atria Investments Inc now owns 945 shares of the biotechnology company’s stock worth $272,000 after purchasing an additional 106 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. boosted its position in shares of United Therapeutics by 7.5% in the second quarter. Resona Asset Management Co. Ltd. now owns 21,840 shares of the biotechnology company’s stock worth $6,271,000 after buying an additional 1,521 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

UTHR has been the subject of several analyst reports. HC Wainwright upped their target price on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday. Wells Fargo & Company raised their target price on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Finally, Bank of America reaffirmed a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $539.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.